

Reference number(s)
1621-A

# SPECIALTY GUIDELINE MANAGEMENT

## FERRIPROX (deferiprone)

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indication

Transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. DOCUMENTATION

Submission of the following information is necessary to initiate the prior authorization review:

- A. Initial requests: pretreatment serum ferritin level
- B. Continuation requests: current serum ferritin level

#### III. CRITERIA FOR INITIAL APPROVAL

##### **Transfusional Iron Overload**

Authorization of 6 months may be granted for treatment of transfusional iron overload due to thalassemia syndromes when both of the following criteria are met:

- A. Pretreatment serum ferritin level is consistently greater than 1000 mcg/L.
- B. Dose of Ferriprox will not exceed 99 mg/kg per day.

#### IV. CONTINUATION OF THERAPY

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when both of the following criteria are met:

- A. Member is experiencing benefit from therapy as evidenced by a decrease in serum ferritin levels as compared to pretreatment baseline.
- B. Serum ferritin level is not consistently below 500 mcg/L.

#### V. REFERENCES

1. Ferriprox [package insert]. Rockville, MD: ApoPharma USA, Inc.; May 2017.
2. Micromedex Solutions [database online]. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: [www.micromedexsolutions.com](http://www.micromedexsolutions.com). Accessed October 15, 2018.
3. AHFS DI (Adult and Pediatric) [database online]. Lexi-Comp, Inc. Hudson, OH. Available at: [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed October 15, 2018.

Reference number(s)
1621-A

4. Clinical Pharmacology [Internet]. Elsevier. Tampa (FL). Available from: <http://www.clinicalpharmacology.com>. Accessed October 15, 2018.
5. Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT) 3<sup>rd</sup> Edition [Internet]. *Thalassaemia International Federation* 2014;20:1-253.